Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Diarrhea × telotristat ethyl × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1 Endocrine 1

Conditions

Serotonin Syndrome 5 Neuroendocrine Tumors 4 Pancreatic Neoplasms 2 Neoplasms 1 Diarrhea 1 Carcinoid Tumor 1 Carcinoid Heart Disease 1 Cachexia 1 Biliary Tract Neoplasms 1

Interventions

Octreotide 6 Irinotecan 6 Loperamide 4 Leucovorin 3 Fluorouracil 3 Calcium Aluminosilicate 3 maltodextrin 2 Probiotics 2 telotristat ethyl 1 shosaiko-to 1 lanreotide 1 isatuximab 1 cabazitaxel 1 bile acid binding proteins 1 XRP6258 1 Theophylline 1 Temozolomide 1 Surveys and Questionnaires 1 Sulfasalazine 1 Sugars 1 Raloxifene Hydrochloride 1 Radiation 1 Prednisone 1 PHY 906 1 Oxaliplatin 1 Long-Term Synaptic Depression 1 Levofloxacin 1 Lapatinib 1 Injections 1 Fecal Microbiota Transplantation 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04713202 2023-02-10

NET-PACS

Big Ten Cancer Research Consortium

Phase 2 Withdrawn

Diarrhea, Neuroendocrine Tumors, Serotonin Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon ⚡